Treatment of fibrotic interstitial lung disease: current approaches and future directions

Kerri A Johannson; Nazia Chaudhuri; Ayodeji Adegunsoye; Paul J Wolters

doi:10.1016/S0140-6736(21)01826-2

Treatment of fibrotic interstitial lung disease: current approaches and future directions

Kerri A Johannson
, Nazia Chaudhuri
, Ayodeji Adegunsoye
, Paul J Wolters

Research output: Contribution to journal › Review article › peer-review

101 Citations (Scopus)

Abstract

Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.

Original language	English
Pages (from-to)	1450-1460
Number of pages	11
Journal	Lancet
Volume	398
Issue number	10309
Early online date	6 Sept 2021
DOIs	https://doi.org/10.1016/S0140-6736(21)01826-2
Publication status	Published (in print/issue) - 16 Oct 2021

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Humans
Lung Diseases, Interstitial/drug therapy
Pulmonary Fibrosis/drug therapy

Access to Document

10.1016/S0140-6736(21)01826-2

Cite this

@article{b0e738f751bb486bb9e053c57c9f2a88,

title = "Treatment of fibrotic interstitial lung disease: current approaches and future directions",

abstract = "Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.",

keywords = "Humans, Lung Diseases, Interstitial/drug therapy, Pulmonary Fibrosis/drug therapy",

author = "Johannson, \{Kerri A\} and Nazia Chaudhuri and Ayodeji Adegunsoye and Wolters, \{Paul J\}",

year = "2021",

month = oct,

day = "16",

doi = "10.1016/S0140-6736(21)01826-2",

language = "English",

volume = "398",

pages = "1450--1460",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "10309",

}

TY - JOUR

T1 - Treatment of fibrotic interstitial lung disease

T2 - current approaches and future directions

AU - Johannson, Kerri A

AU - Chaudhuri, Nazia

AU - Adegunsoye, Ayodeji

AU - Wolters, Paul J

PY - 2021/10/16

Y1 - 2021/10/16

N2 - Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.

AB - Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.

KW - Humans

KW - Lung Diseases, Interstitial/drug therapy

KW - Pulmonary Fibrosis/drug therapy

U2 - 10.1016/S0140-6736(21)01826-2

DO - 10.1016/S0140-6736(21)01826-2

M3 - Review article

C2 - 34499866

SN - 0140-6736

VL - 398

SP - 1450

EP - 1460

JO - Lancet

JF - Lancet

IS - 10309

ER -

Treatment of fibrotic interstitial lung disease: current approaches and future directions

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this